



Universiteit  
Leiden  
The Netherlands

## Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

Erp, P.H. van

### Citation

Erp, P. H. van. (2009, December 16). *Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib*. Retrieved from <https://hdl.handle.net/1887/14515>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14515>

**Note:** To cite this publication please use the final published version (if applicable).

# **Clinical Pharmacology of the Tyrosine Kinase Inhibitors Imatinib and Sunitinib**

**Nielka van Erp**

# Clinical Pharmacology of the Tyrosine Kinase Inhibitors Imatinib and Sunitinib

## Proefschrift

ter verkrijging van  
de graad Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties  
ter verdedigen op woensdag 16 december 2009  
klokke 13:45 uur

door

**Petronella Hubertha van Erp**

geboren te Liempde  
in 1977

The research presented in this thesis was performed at the Department of Clinical Pharmacy  
and Toxicology of Leiden University Medical Center, The Netherlands.

Publication of this thesis was sponsored by:  
AZL Onderzoeks- en Ontwikkelingskrediet (OOK) Apotheek  
Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie (KNMP)

Cover design and layout by: In Zicht Grafisch Ontwerp, Arnhem, [www.promotie-inzicht.nl](http://www.promotie-inzicht.nl)  
Printed by: Ipskamp Drukkers, Enschede

ISBN 978-90-9024737-3

© P.H. van Erp 2009

All rights reserved. No parts of this publication may be reproduced, stored in a retrieval  
system of any nature, or transmitted in any form or by any means, electronic, mechanical,  
photocopying, recording or otherwise, without prior written permission of the publisher.

**Promotor**

Prof. Dr. H.-J. Guchelaar

**Copromotor**

Dr. A.J. Gelderblom

**Overige leden**

Prof. Dr. M. Danhof

Prof. Dr. H.M.W. Verheul, *Vrije Universiteit, Amsterdam*

Prof. Dr. J.H. Beijnen, *Universiteit Utrecht*

Dr. A. Sparreboom, *St. Jude Children's Research Hospital, Memphis, USA*

"Nothing in life is to be feared, it is only to be understood"  
*Marie Curie*

## Contents

|                                                  |                                                                                                                                                                                                                             |            |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 1                                                | General introduction                                                                                                                                                                                                        | 9          |
| 2                                                | Clinical pharmacokinetics of tyrosine kinase inhibitors<br><i>Cancer Treatment Reviews 2009 (in press)</i>                                                                                                                  | 17         |
| <b>Part 1 Clinical Pharmacology of Imatinib</b>  |                                                                                                                                                                                                                             | <b>53</b>  |
| 3                                                | Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib<br><i>Clinical Cancer Research 2007; 13(24):7394-7400</i>                                                                                   | 55         |
| 4                                                | Effect of cigarette smoking on pharmacokinetics, safety and efficacy of imatinib:<br>a study based on data of the Soft Tissue and Bone Sarcoma Group of the EORTC<br><i>Clinical Cancer Research 2008; 14(24):8308-8313</i> | 73         |
| 5                                                | Is rectal administration of imatinib an alternative route for imatinib?<br><i>Cancer Chemotherapy and Pharmacology 2007; 60(4):623-624</i>                                                                                  | 89         |
| <b>Part 2 Clinical Pharmacology of Sunitinib</b> |                                                                                                                                                                                                                             | <b>95</b>  |
| 6                                                | Relationship between CYP3A4 phenotyping and sunitinib exposure in cancer patients                                                                                                                                           | 97         |
| 7                                                | Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity<br><i>Journal of Clinical Oncology 2009 (published online ahead of print, August 10, 2009)</i>                                             | 111        |
| 8                                                | Clinically irrelevant effect of grapefruit juice on the steady-state sunitinib exposure<br><i>Submitted</i>                                                                                                                 | 131        |
| 9                                                | Mitotane has a strong inducing effect on CYP3A4 activity<br><i>Submitted</i>                                                                                                                                                | 149        |
| 10                                               | Absorption of cytochrome P450 3A4 inhibiting furanocoumarins from grapefruit<br>juice after oral administration<br><i>Submitted</i>                                                                                         | 159        |
| <b>Part 3 Appendix</b>                           |                                                                                                                                                                                                                             | <b>171</b> |
| 11                                               | General Discussion and Future Perspectives                                                                                                                                                                                  | 173        |
|                                                  | Summary                                                                                                                                                                                                                     | 185        |
|                                                  | Nederlandse samenvatting                                                                                                                                                                                                    | 193        |
|                                                  | Dankwoord                                                                                                                                                                                                                   | 203        |
|                                                  | List of Publications                                                                                                                                                                                                        | 205        |
|                                                  | Curriculum Vitae                                                                                                                                                                                                            | 207        |